Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 49 | ECE2017 | Next issue

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

Card image cap
20-23 May 2017, Lisbon, Portugal Further information

Symposia

Endo Oncology: prolactin, GH and metabolic hormones in oncology pathogenesis (Endorsed by Endocrine Connections)

ea0049s23.1 | Endo Oncology: prolactin, GH and metabolic hormones in oncology pathogenesis (Endorsed by Endocrine Connections) | ECE2017

Prolactin regulation of prostate stem cells: potential implications in prostate cancer

Goffin Vincent

Prostate stem cells have been proposed to participate in prostate cancer initiation. Furthermore, based on their androgen-independence, they are suspected to trigger prostate cancer recurrence when the tumor is no longer responsive to anti-androgens. Therefore better understanding the regulation of this particular cell pool may have important therapeutic relevance. In the human prostate, expression of prolactin (PRL) and activation of its major downstream signaling effector St...

ea0049s23.2 | Endo Oncology: prolactin, GH and metabolic hormones in oncology pathogenesis (Endorsed by Endocrine Connections) | ECE2017

Is GH a cancer growth factor?

Melmed Shlomo

Acromegaly is associated with increased soft tissue neoplasms, while GH deficient patients are protected from cancer development. Both environmental and age-related signals lead to cellular senescence and cell cycle dysregulation. We have shown that DNA damage-induced cellular senescence increases GH by inducing p53. GH, in turn, suppresses tumor suppressor proteins in both pituitary and nonpituitary cells.These observations led us to propose that intracellular epithelial GH i...